

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

Convenient Synthesis of Wogonin, A Flavonoid Natural Product with Extensive Pharmacological Activity

Zhi-Yu Li^{ab}; Xin Cao^{ab}; Xin Wang^b; Qing-Long Guo^a; Qi-Dong You^{ab}

^a Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, P. R. China ^b Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, P. R. China

To cite this Article Li, Zhi-Yu , Cao, Xin , Wang, Xin , Guo, Qing-Long and You, Qi-Dong(2009) 'Convenient Synthesis of Wogonin, A Flavonoid Natural Product with Extensive Pharmacological Activity', *Organic Preparations and Procedures International*, 41: 4, 327 – 330

To link to this Article: DOI: 10.1080/00304940903102739

URL: <http://dx.doi.org/10.1080/00304940903102739>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

OPPI BRIEFS

Convenient Synthesis of Wogonin, A Flavonoid Natural Product with Extensive Pharmacological Activity

Zhi-Yu Li,^{1,2} Xin Cao,^{1,2} Xin Wang,² Qing-Long Guo,¹
and Qi-Dong You^{1,2}

¹Jiangsu Key Laboratory of Carcinogenesis and Intervention,
China Pharmaceutical University Nanjing, P. R. China

²Department of Medicinal Chemistry, China Pharmaceutical University Nanjing,
P. R. China

Wogonin (5,7-dihydroxy-8-methoxyflavone, **5**), a flavonoid natural product first isolated from *Scutellaria Radix*, is well-known for its anti-inflammation,¹ anti-allergy,² anti-tumor³ and anti-hepatitis B virus⁴ properties. Owing to its extensive applications in medical treatment, researchers have developed several synthetic pathways to obtain this important natural product since the early part of the last century.^{5,6} The initial total syntheses of *wogonin* were based on the common synthetic approaches to flavonoids through Baker-Venkataraman rearrangement^{6,7} or intramolecular Wittig reaction.⁸ However, neither of these two strategies was efficient for large scale production of the compound. Recently Huang *et al.*⁹ reported a simplified synthesis of *wogonin* (**5**) and *oroxylin A* (**6**) from 3,4,5-trimethoxyphenol (**1**) and cinnamoyl chloride (**2**). As shown in Figure 1, the flavone nucleus was obtained from intermediate **4** wherein the two hydroxyl groups compete for the addition to the α,β -unsaturated ketone moiety. Evidently, the C₆-OH is more active than C₂-OH since the yield of *oroxylin A* was nearly double that of *wogonin*. Moreover, this synthetic route is not an ideal process for industrial production because the two products are difficult to separate.

Prompted by this earlier report on the construction of the flavone nucleus, we launched our own studies, focusing on avoiding the undesired flavone derivative **6** in the total synthesis of pure *wogonin* (Figure 2). To avoid the competitive addition process while forming the flavone nucleus, we utilized intermediate **8** which has only one reactive position. Intermediate **8** was synthesized in >90% yield from 2,5-dimethoxybenzene-1,3-diol (**7**)

Submitted March 12, 2009.

Address correspondence to Qi-Dong You, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University Nanjing 210009, P. R. China. E-mail: youqidong@gmail.com




Figure 1

which was prepared according to Geissman *et al.*¹⁰ and cinnamoyl chloride (**2**) in the presence of $\text{BF}_3\text{-Et}_2\text{O}$. Subsequently, **8** was smoothly cyclized with I_2 in dimethyl sulfoxide (DMSO) to afford 5-methoxywogonin (**9**) in > 90% yield.¹¹ Finally, *wogonin* was obtained after selective removal of the 5-methoxy group with anhydrous AlCl_3 in acetonitrile (CH_3CN) in good yield (84%). The overall yield of **5** from **7** was 68%.

After paying attention to the avoidance of the undesired flavone derivative **6** during the synthesis of *wogonin* following the method of Huang *et al.*,⁹ we evaluated two other literature approaches of the final intermediate 5-methoxywogonin (**9**). Suan *et al.* reported that **9** could be obtained from **7** by two steps: firstly acetylating and then reacting with sodium benzoate and benzoic anhydride.¹² Additionally, Rivaille *et al.*¹³ reported that **9** could be obtained directly by cyclization of compound **7** with acetyl benzoylacetate. However, both of these methods have many drawbacks such as poor yields, high reaction temperature and long reaction time, all of which made these approaches unsuitable for scale up. Thus, our synthesis was comparatively more efficient and simple.




Figure 2

In conclusion, an improved strategy for the total syntheses of *wogonin* is reported. Compared with the previously reported methods, this synthetic route is more convenient and proceeds to give pure *wogonin* in an overall yield of 68%. This novel synthetic pathway to *wogonin* is of great value for the large scale and industrial preparation of this important flavonoid natural product.

Experimental Section

Reagents, solvents and starting materials were purchased from commercial sources and were used without further purification unless noted. Melting points were determined on a micro-melting point apparatus XT-4(Beijing Taike instrument company, China). ¹H-NMR spectra were recorded on a Bruker AMX-300 spectrometer. Chemical shifts are reported in δ values relative to TMS as an internal standard. Coupling constants were in units of Hertz (Hz). Mass spectra (EI) were obtained on Shimadzu GCMS-QP2010. IR spectra were collected using a Nicolet Impact 410 instrument. All of the reactions were performed under an inert atmosphere of nitrogen.

(E)-1-(2,4-Dihydroxy-3,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one (8)

A solution of commercially available 2,5-dimethoxybenzene-1,3-diol (**7**, 10.0 g, 60 mmol) and cinnamoyl chloride (**2**, 18.0 g, 70 mmol) in BF₃-Et₂O solution (20 mL) was heated at reflux for 30 min, cooled and poured into water. The resulting solid was collected and recrystallized from methanol to give compound **8** (16.2 g, 94%) as reddish-yellow crystals, mp 210°C, *lit.*¹⁴ 124–125°C. The literature report¹⁴ indicates that compound **8** was separated from the seeds and leaves of *Polygonum senegalense* by chromatography on silica gel. However, we found that authentic **8** prepared by our method when mixed with authentic **2** and **7**, could not be separated and purified by chromatography on silica gel since it was totally adsorbed on the silica gel. This would explain the much lower mp. reported in the literature.¹⁴

¹H-NMR (300 MHz, CDCl₃): δ 4.00 (6H, s), 6.13 (1H, s), 7.48–7.52 (3H, m), 7.68–7.70 (2H, m), 8.03 (1H, d, *J* = 15.2 Hz), 8.33 (1H, d, *J* = 15.2 Hz). The OH hydrogens could not be observed neither in DMSO-d₆ nor in CDCl₃. The two methoxy groups appear to have identical chemical shifts. ¹³C-NMR (75MHz, DMSO-d₆): δ 56.9, 60.2, 93.9, 104.3, 121.7, 129.3, 129.7, 130.1, 132.2, 134.1, 148.7, 158.2, 160.7, 165.6, 180.5. IR (KBr): 3400, 3216, 3011, 1606, 1526, 1445, 1374, 1250, 1129 cm⁻¹. EI-MS (*m/z*): 300 (*M*⁺), 285, 269, 230, 223, 196, 181, 167, 153.

Anal. Calcd for C₁₇H₁₆O₅: C, 67.99; H, 5.37. Found: C, 67.92; H, 5.45.

7-Hydroxy-5,8-dimethoxy-2-phenyl-4H-chromen-4-one (9)

A solution of **8** (8.0 g, 27 mmol) and iodine (50 mg) in DMSO (35 mL) was stirred at 140°C for 1 h and then carefully poured onto crushed ice. The precipitate was collected and washed with 20% Na₂SO₃ solution and pure water. The crude product was recrystallized from aqueous methanol (3:1) to give **9** as a pale yellow solid (7.3 g, 95%), mp 287–288°C, *lit.*^{12,13} 287–288°C.

¹H-NMR (300 MHz, CDCl₃): δ 3.76 (3H, s), 3.85 (3H, s), 6.48 (1H, s), 6.77 (1H, s), 7.57–7.60 (3H, m), 8.01–8.05 (m, 2H). ¹³C-NMR (75MHz, DMSO-d₆): δ 55.7, 60.9, 96.9, 106.2, 107.8, 125.7, 128.8, 129.1, 131.1, 131.3, 151.5, 155.4, 155.7, 159.0, 175.7. IR (KBr): 3123, 1635, 1579, 1501, 1397, 1339, 1207, 1114 cm⁻¹. EI-MS (*m/z*): 298 (*M*⁺), 283, 255, 153.

Wogonin (5,7-Dihydroxy-8-methoxyflavone, 5)

A solution of **9** (5.0 g, 17 mmol) in acetonitrile (250 mL) was added anhydrous AlCl₃ (11.0 g, 17 mmol) at 0°C under a nitrogen atmosphere. The reaction mixture was heated at reflux for 4 h and then poured into 200 mL of 3N HCl. Extraction with ethyl acetate (200 mL), drying over anhydrous Na₂SO₄ followed by evaporation of the solvent gave the crude product which was recrystallized from ethanol to give a yellow solid (15.0 g, 84%), mp 201–202°C, *lit.*⁷ 198–199°C.

¹H-NMR (300MHz, DMSO-d₆): δ 3.86 (3H, d, *J* = 1.8 Hz), 6.32 (1H, s), 7.01 (1H, s), 7.61–7.64 (3H, m), 8.07–8.09 (2H, m), 10.82 (1H, s), 12.51 (1H, d, *J* = 1.8 Hz). ¹³C-NMR (75MHz, DMSO-d₆): δ 61.0, 99.1, 103.7, 105.3, 126.2, 127.8, 129.2, 130.8, 132.0, 149.6, 156.2, 157.3, 163.0, 182.0. IR (KBr) : 3411, 1660, 1579 cm⁻¹. EI-MS (*m/z*): 284 (*M*⁺).

Acknowledgements

The authors gratefully acknowledge financial support from the National Natural Science Foundations of China (Grant No. 30701032 and 90713038).

References

1. C. K. Han, M. J. Son, H. W. Chang, Y. S. Chi, H. Park and H. P. Kim, *Biol. Pharm. Bull.*, **28**, 1366 (2005).
2. M. C. Tai, S. Y. Tsang, L. Y. F. Chang and H. Xue, *CNS Drug Reviews*, **11**, 141 (2005).
3. S. C. Fas, S. Baumann, J. Y. Zhu, M. Giaisi, M. K. Treiber, U. Mahlkecht, P. H. Krammer and M. L. Weber, *Blood*, **108**, 3700 (2006).
4. Q. L. Guo, L. Zhao, Q. D. You, Y. Yang, H. Y. Gu, G. L. Song, N. Lu, and J. Xin, *Antiviral Res.*, **74**, 16 (2007).
5. J. Allan and R. Robinson, *J. Chem. Soc.*, **12s**, 2192 (1924).
6. P. K. Venkatswara, R. K. Visweswara and R. Seshadri, *Proc. Indian Acad. Sci.*, **26A**, 13 (1943).
7. H. S. Mahal and K. Venkataraman, *Curr. Sci.*, **2**, 214 (1933).
8. A. Hercouet, M. LeCorre and Y. LeFloc'h, *Synthesis*, 597 (1982).
9. W. H. Huang, P. Y. Chien and C. H. Yang, *Chem. Pharm. Bull.*, **51**, 339 (2003), *Chem. Abstr.*, **139**, 149434r, (2003).
10. T. A. Geissman and T. G. Halsall, *J. Am. Chem. Soc.*, **73**, 1280 (1951).
11. D. C. G. A. Pinto, A. M. S. Silva and J. A. S. Cavaleiro, *J. Heterocyclic. Chem.*, **33**, 1887 (1996).
12. R. C. Shah, C. R. Mehta and T. S. Wheeler, *J. Chem. Soc.*, 1555 (1938).
13. P. Rivaille and C. Mentzer, *C. R Acad. Sc. Paris, Série C*, **268**, 2213 (1969), *Chem. Abstr.*, **71**, 61142k, (1969).
14. A. Maradufu and J. H. Ouma, *Phytochemistry*, **17**, 823 (1978).